These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35628480)

  • 61. Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes.
    Abbas HA; Reville PK; Jiang X; Yang H; Reuben A; Im JS; Little L; Sinson JC; Chen K; Futreal A; Garcia-Manero G
    Front Immunol; 2021; 12():659625. PubMed ID: 33912187
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
    Stein EM; Bonifacio G; Latremouille-Viau D; Shi S; Guerin A; Wu EQ; Sadek I; Cao X
    Leuk Lymphoma; 2021 Jun; 62(6):1411-1421. PubMed ID: 33430673
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
    Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
    Mongiorgi S; De Stefano A; Ratti S; Indio V; Astolfi A; Casalin I; Pellagatti A; Paolini S; Parisi S; Cavo M; Pession A; McCubrey JA; Suh PG; Manzoli L; Boultwood J; Finelli C; Cocco L; Follo MY
    Clin Epigenetics; 2023 Feb; 15(1):27. PubMed ID: 36803590
    [TBL] [Abstract][Full Text] [Related]  

  • 65. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schuler E; Wagner-Drouet EM; Ajib S; Bug G; Crysandt M; Dressler S; Hausmann A; Heidenreich D; Hirschbühl K; Hoepting M; Jost E; Kaivers J; Klein S; Koldehoff M; Kordelas L; Kriege O; Müller LP; Rautenberg C; Schaffrath J; Schmid C; Wolff D; Haas R; Bornhäuser M; Schroeder T; Kobbe G;
    Ann Hematol; 2021 Apr; 100(4):959-968. PubMed ID: 33191481
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
    Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
    Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.
    Karantanos T; Teodorescu P; Arvanitis M; Perkins B; Jain T; DeZern AE; Dalton WB; Christodoulou I; Paun BC; Varadhan R; Esteb C; Rajkhowa T; Bonifant C; Gondek LP; Levis MJ; Yegnasubramanian S; Ghiaur G; Jones RJ
    Haematologica; 2023 Jul; 108(7):1886-1899. PubMed ID: 36519323
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
    Borthakur G; Ahdab SE; Ravandi F; Faderl S; Ferrajoli A; Newman B; Issa JP; Kantarjian H
    Leuk Lymphoma; 2008 Apr; 49(4):690-5. PubMed ID: 18398735
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
    Wong JJ; Lau KA; Pinello N; Rasko JE
    Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Azacitidine Use for Myeloid Neoplasms.
    El Fakih R; Komrokji R; Shaheen M; Almohareb F; Rasheed W; Hassanein M
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):e147-e155. PubMed ID: 29478947
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
    Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
    Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
    Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
    J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
    Feld J; Tremblay D; Navada SC; Silverman LR
    Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.